Header links
Intranet
Donate now
image/svg+xml Map
Contact us

RESPONSE: Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de Seladelpar en paci

RESPONSE: Estudio de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de Seladelpar en pacientes con colangitis biliar primaria (CBP) y una respuesta insuficiente o intolerancia al ácido ursodesoxicólico (UDCA).RESPONSE: A placebo-controlled, randomized, phase 3 study to evaluate the efficacy and safety of seladelpar in patients with primary biliary cholangitis (PBC) and an inadequate response to or an intolerance to ursodeoxycholic acid (UDCA)

Contact
  • Protocol code: CB8025-32048
  • EudraCT code: 2020-004348-27
  • Pathology: Malalties del sistema digestiu
  • Principal investigator:  Vargas Blasco, Victor Manuel
  • Research group:  Malalties hepàtiques
  • Service: Hepatologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.